India's quiet NTM lung crisis gets a clinical push
Indian pulmonologists are urging early diagnosis of nontuberculous mycobacterial lung disease, framing it as a slow-burn epidemic hiding inside India's much larger tuberculosis fight.
On 18 July 2026, a clutch of senior Indian chest physicians used a public awareness push to put a number on a disease that India's tuberculosis machinery has been quietly losing cases to for years. Nontuberculous mycobacterial, or NTM, lung disease is a chronic bacterial infection that mimics tuberculosis on a chest X-ray, drags on for months, and frequently gets treated as TB that will not go away. The physicians' message, carried in a 2:30 UTC piece on ThePrint's India health feed, was blunt: the disease must be diagnosed and treated early, because, if left untreated, it can cause progressive lung damage, respiratory failure and even death.
That single warning, attributed to Dr S.K. Sharma, former head of the department of medicine at AIIMS, New Delhi, does more than flag a clinical risk. It exposes a structural gap in how India screens, codes and pays for respiratory illness. TB has the infrastructure, the public messaging, the donor pipelines and the case definitions. NTM has, until recently, had almost none of that, even though the organism behaves enough like Mycobacterium tuberculosis to fool frontline clinics for years.
The disease India's TB programme keeps missing
NTM refers to a family of environmental mycobacteria, most commonly Mycobacterium avium complex and M. abscessus, picked up from soil and water rather than person to person. In the lungs, it behaves like a slow-moving cousin of TB: fever, cough, weight loss, cavities on imaging, and damage that does not reverse once it is established. The clinical stakes Sharma flagged in ThePrint's 18 July 2026 dispatch are not abstract. Progressive lung damage and respiratory failure are the documented endpoints in immunocompromised patients and in people with underlying structural lung disease, and the mortality numbers track closely with how late treatment starts.
The Indian context makes the timing of the warning significant. India carries the world's largest TB burden, and the government's flagship TB programme has spent a decade expanding testing, offering free drugs, and rolling out new shorter-course regimens. That investment works against TB. It does not automatically work against NTM, which does not respond to the standard first-line TB regimens that dominate the public supply chain.
A long diagnostic trap
The clinical pattern is the trap. A patient presents with cough, weight loss and a cavity on chest X-ray. Under India's TB protocols, that patient is presumptively started on anti-tubercular therapy, often without a species-level confirmation of the organism. If symptoms do not improve, the reflex is to extend TB treatment, switch regimens, or label the case drug-resistant TB, all without necessarily sending sputum for the mycobacterial culture and identification that would pick up NTM.
That diagnostic reflex has a cost. NTM disease requires different drugs, typically a macrolide-based multidrug regimen lasting 12 to 24 months, and it does not respond to the rifampicin-based protocols that anchor India's public TB pharmacy. A patient who spends a year on the wrong regimen is a patient whose lung damage has compounded. That is the early-treatment point Sharma pressed on in ThePrint's 18 July 2026 health alert: the disease's progression is not theoretical, and the window in which treatment reverses damage is narrower than many clinicians assume.
What the existing data does and does not say
NTM is not new to Indian medicine. Case series from tertiary chest hospitals have flagged it for at least a decade, and a body of Indian microbiology literature documents NTM isolates from respiratory samples. What is missing is a national prevalence picture. India does not run a dedicated NTM surveillance system, and the country is not a routine participant in the global NTM registry work that has built up clearer numbers for the United States, Japan, South Korea and parts of Europe. The result is a paradox: clinicians in Indian tertiary centres know NTM exists, and they know the cases are getting through, but the public-health system does not yet count them as a separate line item.
That gap matters because it dictates everything downstream, from drug procurement to insurance coding to what the government tells donors. A disease that is not counted is a disease that does not get a budget line, and a disease without a budget line relies on the diagnostic reflex of whatever system already exists around it, in this case the TB programme.
The structural frame, in plain language
India's respiratory-disease architecture was built for TB, and it is still being paid for as if TB were the only chronic bacterial lung disease that matters. The public clinics, the free-drug supply chain, the GeneXpert machines, the ASHA worker screening protocols and the donor reporting lines all run through that architecture. NTM sits underneath it, clinically similar enough to slip through the same net, biologically different enough to need a different drug regimen and a different diagnostic step. Sharma's warning, as carried by ThePrint on 18 July 2026, is the clearest signal yet from a senior AIIMS clinician that the gap is producing avoidable harm at scale, and that closing it will require India to treat NTM as a distinct disease, not a TB-adjacent curiosity.
The stakes are concrete. Every year that NTM diagnosis is folded into the TB reflex is a year in which a meaningful share of chronic, non-resolving respiratory illness in Indian adults is treated with the wrong drugs, generating costs the public system absorbs, drug resistance the global community tracks, and lung damage that does not reverse. India's larger TB fight is the obvious anchor, but the country's respiratory-medicine establishment is now telling anyone listening that the architecture needs a second column for a disease that, until recently, was a footnote in microbiology textbooks.
This publication framed the clinical warning from ThePrint as a structural story about diagnostic capacity and disease coding, rather than a generic public-health advisory, on the view that the gap between TB and NTM is the part Indian readers are not getting elsewhere on 18 July 2026.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://t.me/thePrintIndia
- https://en.wikipedia.org/wiki/Nontuberculous_mycobacteria
- https://en.wikipedia.org/wiki/Mycobacterium_avium_intracellulare_infection
- https://en.wikipedia.org/wiki/Tuberculosis_in_India